LAURUS LABS LTD

Company Introduction:

LAURUS LABS LTD is a leading Indian pharmaceutical and biotechnology company. It is primarily engaged in the research, development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs), intermediates, and Generic Finished Dosage Forms (FDFs). The company also has a significant presence in custom synthesis for global pharmaceutical companies. Laurus Labs operates multiple state-of-the-art manufacturing facilities that comply with global regulatory standards, including those of the US FDA, EDQM, and WHO. It is known for its strong R&D capabilities and its focus on anti-retroviral, oncology, and other therapeutic areas.

Type: Manufacturer

LAURUS LABS LTD, an Indian company, primarily manufactures and sells Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) across various therapeutic areas. Their product portfolio includes a wide range of Antiretroviral (ARV) APIs such as Tenofovir, Lamivudine, Emtricitabine, Dolutegravir, Efavirenz, Nevirapine, and Rilpivirine. They also produce APIs for Hepatitis C, including Sofosbuvir, Ledipasvir, Velpatasvir, and Daclatasvir. In the Oncology segment, their API offerings include Cabazitaxel, Pemetrexed, Erlotinib, Dasatinib, Imatinib, Lapatinib, Sunitinib, Sorafenib, and Pazopanib. Beyond these, Laurus Labs manufactures APIs for cardiovascular, anti-diabetic, and other therapeutic categories. In Finished Dosage Forms, they offer various formulations, often combination therapies, for ARV, Hepatitis C, and Oncology treatments. Additionally, the company provides Contract Development and Manufacturing Organization (CDMO) services for intermediates and APIs, and is involved in bio-manufacturing and biosimilar development.